GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Capex-to-Operating-Cash-Flow

Harrow (Harrow) Capex-to-Operating-Cash-Flow : 0.02 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Harrow Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Harrow's Capital Expenditure for the three months ended in Dec. 2023 was $-0.20 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $8.70 Mil.

Hence, Harrow's Capex-to-Operating-Cash-Flow for the three months ended in Dec. 2023 was 0.02.


Harrow Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Harrow's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Capex-to-Operating-Cash-Flow Chart

Harrow Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.93 - 5.61 4.56 39.73

Harrow Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.27 - 0.02

Competitive Comparison of Harrow's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harrow's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harrow's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Harrow's Capex-to-Operating-Cash-Flow falls into.



Harrow Capex-to-Operating-Cash-Flow Calculation

Harrow's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-152.553) / 3.84
=39.73

Harrow's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.203) / 8.696
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harrow  (NAS:HROW) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Harrow Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Harrow's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Harrow (Harrow) Business Description

Industry
Traded in Other Exchanges
N/A
Address
102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205
Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.
Executives
Mark L Baum director, 10 percent owner, officer: Chief Executive Officer C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence director 354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll officer: VP, Accounting and Reporting 437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer director, 10 percent owner, officer: Chairman of the Board 1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc other: Institutional Investor 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad other: Managing Mbr of Longboard Cap. 1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards officer: Chief Operating Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi director 2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni 10 percent owner 1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek officer: Chief Commercial Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

Harrow (Harrow) Headlines

From GuruFocus

Harrow Launches VIGAMOX� in the U.S.

By Business Wire 07-31-2023

Melt Pharmaceuticals Provides Corporate Update

By Business Wire 01-03-2024

Harrow Announces New $100 Million Secured Credit Facility with Oaktree

By Business Wire Business Wire 03-28-2023